|
1
|
Fisher EJ, Chaloner K, Cohn DL, et al: The
safety and efficacy of adefovir dipivoxil in patients with advanced
HIV disease: a randomized, placebo-controlled trial. AIDS.
15:1695–1700. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dando T and Plosker G: Adefovir dipivoxil:
a review of its use in chronic hepatitis B. Drugs. 63:2215–2234.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marcellin P, Chang TT, Lim SG, et al:
Adefovir dipivoxil for the treatment of hepatitis B e
antigen-positive chronic hepatitis B. N Engl J Med. 348:808–816.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hadziyannis SJ, Tassopoulos NC, Heathcote
EJ, et al: Adefovir dipivoxil for the treatment of hepatitis B e
antigen-negative chronic hepatitis B. N Engl J Med. 348:800–807.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tamori A, Enomoto M, Kobayashi S, et al:
Add-on combination therapy with adefovir dipivoxil induces renal
impairment in patients with lamivudine-refractory hepatitis B
virus. J Viral Hepat. 17:123–129. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Marcellin P, Chang TT, Lim SG, et al:
Long-term efficacy and safety of adefovir dipivoxil for the
treatment of hepatitis B e antigen-positive chronic hepatitis B.
Hepatology. 48:750–758. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pearce-Smith N and Hunter J: The
introduction of librarian tutors into the Teaching Evidence-Based
Medicine week in Oxford, UK. Health Info Libr J. 22:146–149. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jadad AR, Moore RA, Carroll D, et al:
Assessing the quality of reports of randomized clinical trials: is
blinding necessary? Control Clin Trials. 17:1–12. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Perrillo R, Hann HW, Mutimer D, et al:
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis
B with YMDD mutant hepatitis B virus. Gastroenterology. 126:81–90.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Izzedine H, Hulot JS, Launay-Vacher V, et
al: Renal safety of adefovir dipivoxil in patients with chronic
hepatitis B: two double-blind, randomized, placebo-controlled
studies. Kidney Int. 66:1153–1158. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lim SG, Marcellin P, Tassopoulos N, et al:
Clinical trial: effects of adefovir dipivoxil therapy in Asian and
Caucasian patients with chronic hepatitis B. Aliment Pharmacol
Ther. 26:1419–1428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jonas MM, Kelly D, Pollack H, et al:
Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in
children and adolescents (age 2 to <18 years) with chronic
hepatitis B. Hepatology. 47:1863–1871. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Manolakopoulos S, Striki A, Deutsch M, et
al: Long-term adefovir plus lamivudine therapy does not decrease
creatinine clearance in HBe Ag-negative chronic hepatitis B
patients. Liver Int. 31:1525–1532. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mauss S, Berger F, Filmann N, et al:
Effect of HBV polymerase inhibitors on renal function in patients
with chronic hepatitis B. J Hepatol. 55:1235–1240. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ha NB, Ha NB, Garcia RT, et al: Renal
dysfunction in chronic hepatitis B patients treated with adefovir
dipivoxil. Hepatology. 50:727–734. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gu SW, Zhao B, Sun YY, et al: The effect
of different doses of adefovir dipivoxil on renal function. Chin
Hepatol. 15:247–250. 2010.(In Chinese).
|
|
17
|
Yu JH, Shi JP, Wu J, et al: Efficacy and
safety of lamivudine plus adefovir combination therapy and
entecavir monotherapy for chronic hepatitis B patients. Zhonghua
Gan Zang Bing Za Zhi. 19:88–92. 2011.(In Chinese). PubMed/NCBI
|
|
18
|
Li X, Zhong C, Yang S, et al: Influence of
adefovir dipivoxil or telbivudine monotherapy on renal function of
patients with chronic hepatitis B. Nan Fang Yi Ke Da Xue Xue Bao.
32:826–829. 2012.(In Chinese). PubMed/NCBI
|
|
19
|
Lampertico P, Viganò M, Manenti E, et al:
Low resistance to adefovir combined with lamivudine: a 3-year study
of 145 lamivudine-resistant hepatitis B patients. Gastroenterology.
133:1445–1451. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vassiliadis TG, Giouleme O, Koumerkeridis
G, et al: Adefovir plus lamivudine are more effective than adefovir
alone in lamivudine-resistant HBe Ag-chronic hepatitis B patients:
a 4-year study. J Gastroenterol Hepatol. 25:54–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim YJ, Cho HC, Sinn DH, et al: Frequency
and risk factors of renal impairment during long-term adefovir
dipivoxil treatment in chronic hepatitis B patients. J
Gastroenterol Hepatol. 27:306–312. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu MF, Qian JC, Lu L, et al: Three-year
efficacy and side effect of adefovir dipivoxil for the treatment of
the old patients with chronic hepatitis B virus infection. Zhonghua
Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 26:379–381. 2012.(In
Chinese). PubMed/NCBI
|
|
23
|
Tanaka M, Suzuki F, Seko Y, et al: Renal
dysfunction and hypophosphatemia during long-term lamivudine plus
adefovir dipivoxil therapy in patients with chronic hepatitis B. J
Gastroenterol. 49:470–480. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Peters MG, Hann HW, Martin P, et al:
Adefovir dipivoxil alone or in combination with lamivudine in
patients with lamivudine-resistant chronic hepatitis B.
Gastroenterology. 126:91–101. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Seto WK, Liu K, Fung J, et al: Outcome of
lamivudine-resistant chronic hepatitis B after up to 5 years of
combination therapy with adefovir. Antivir Ther. 17:1255–1262.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schiff ER, Lai CL, Hadziyannis S, et al:
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in
pre- and post-liver transplantation patients. Hepatology.
38:1419–1427. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schiff E, Lai CL, Hadziyannis S, Neuhaus
P, et al: Adefovir dipivoxil for wait-listed and post-liver
transplantation patients with lamivudine-resistant hepatitis B:
final long-term results. Liver Transpl. 13:349–360. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Byar DP, Simon RM, Friedewald WT, et al:
Randomized clinical trials. Perspectives on some recent ideas. N
Engl J Med. 295:74–80. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Abel U and Koch A: The role of
randomization in clinical studies: myths and beliefs. J Clin
Epidemiol. 52:487–497. 1999.PubMed/NCBI
|
|
30
|
Benson K and Hartz AJ: A comparison of
observational studies and randomized, controlled trials. N Engl J
Med. 342:1878–1886. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Levey AS, Bosch JP, Lewis JB, et al: A
more accurate method to estimate glomerular filtration rate from
serum creatinine: a new prediction equation. Modification of Diet
in Renal Disease Study Group. Ann Intern Med. 130:461–470. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cockcroft DW and Gault MH: Prediction of
creatinine clearance from serum creatinine. Nephron. 16:31–41.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Levey AS, Stevens LA, Schmid CH, et al: A
new equation to estimate glomerular filtration rate. Ann Intern
Med. 150:604–612. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lujan PR, Chiurchiu C, Douthat W, et al:
CKD-EPI instead of MDRD for candidates to kidney donation.
Transplantation. 94:637–641. 2012. View Article : Google Scholar : PubMed/NCBI
|
